152628-19-8

Basic information

• Product Name: 12,13-Dihydro-2,10-difluoro-5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
• Synonyms: 12,13-Dihydro-2,10-difluoro-5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione
• CAS NO: 152628-19-8
• Molecular Formula: C20H13F2N3O2
• Molecular Weight: 365.3329264
• Mol File: 152628-19-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.728±0.06 g/cm3(Predicted)
• PKA: 9.74±0.20(Predicted)
• CAS DataBase Reference: 12,13-Dihydro-2,10-difluoro-5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 12,13-Dihydro-2,10-difluoro-5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione(152628-19-8)
• EPA Substance Registry System: 12,13-Dihydro-2,10-difluoro-5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione(152628-19-8)

Safety Data

• Hazardous Substances Data: 152628-19-8(Hazardous Substances Data)

Usage

Chemical class

Indole-derived molecules

Biological activity

Potent inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP)

Therapeutic potential

Treatment of cancer and other diseases

Structural features

Presence of difluoromethyl groups
Carbonyl functional group

Potency and selectivity

High potency and selectivity as a PARP inhibitor

Ongoing research

Aiming to develop new and effective treatments for cancer and other PARP-related diseases
These properties highlight the compound's potential as a therapeutic agent for various diseases, particularly cancer, due to its ability to inhibit the PARP enzyme. The unique structural features contribute to its potency and selectivity, making it a promising candidate for further research and development.

Upstream product

• 84-58-2 2,3-dicyano-5,6-dichloro-p-benzoquinone 
• 152628-10-9 2,3-bis-(6-fluoro-1H-indol-3-yl)-maleimide 

Relevant articles and documents

Design and Synthesis of a Fluoroindolocarbazole Series as Selective Topoisomerase I Active Agents. Discovery of Water-Soluble 3,9-Difluoro-12,13-dihydro-13-[6-amino-β-D-glucopyranosyll]-5H,13H-benzo[b] -thienyl[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (BMS-251873) with Curative Antitumor Activity against Prostate Carcinoma Xenograft Tumor Model

A series of fluoroindolocarbazoles were studied with respect to their topoisomerase I activity, cytotoxicity, selectivity, and in vivo antitumor activity. Emerging from this series was BMS-251873, a potential clinical candidate possessing a robust pharmacological profile including curative antitumor activity against prostate carcinoma.

Indolocarbazoles: Potent, selective inhibitors of human cytomegalovirus replication

In our search for new, safer anti-HCMV agents, we discovered that the natural product Arcyriaflavin A (1a) was a potent inhibitor of HCMV replication in cell culture. A series of analogues (symmetrical indolocarbazoles) was synthesised to investigate structure-activity relationships in this series against a range of herpes viruses (HCMV, VZV, HSV1, and 2). This identified a number of novel, selective and potent inhibitors of HCMV, 12,13-dihydro-2,10-difluoro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-(6H)-dione (1d) being the best example (IC50=40nM, therapeutic index >1450). Compounds described in this series were generally poor inhibitors of protein kinase C βII, and no correlation was found between the ability to inhibit HCMV and the enzyme PKC. Copyright (C) 1999 Elsevier Science Ltd.